Secures new $10.0 million debt facility to replace remaining $7.85 million of Avenue Capital debt Improves cash position enabling Clene to generate the additional data to support the new drug application of CNM-Au8® for ALS via an accelerated regulatory pathwayCarries a 12% interest rate per annum and is secured by all assets of CleneIncludes conversion feature on 65% of the new debt facility at a fixed conversion price of $5.67, a 130% premium to Clene’s closing stock price on the day of signing SALT LAKE ...

Clene Inc. (CLNN) came out with a quarterly loss of $1.22 per share versus the Zacks Consensus Estimate of a loss of $1.34. This compares to loss of $0.40 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 8.96%. A quarter ago, it was expected that this company would post a loss of $1.60 per share when it actually produced a loss of $1.06, delivering a surprise of 33.75%.Over the last four quarters, the company has surpassed cons ...

Exhibit 99.1 CLENE REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS AND RECENT OPERATING HIGHLIGHTS ● Clene met with the U.S. Food and Drug Administration (FDA) on November 1, 2024 in a Type C meeting to discuss the potential for an accelerated approval pathway in ALS and are awaiting meeting minutes ● Cash, cash equivalents and marketable securities of $14.6 million as of September 30, 2024 ● Amended debt agreement with Avenue Capital to defer principal payments and extend maturity of facility to second quarte ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ to _____________ Commission file number: 01-39834 | --- | --- | --- | |--------------------------------------------------------------------- ...

SALT LAKE CITY, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly-owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurological diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that on September 30, 2024 it entered into a securities purchase agreement with a healthcare focus ...

SALT LAKE CITY, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), announced today that it will meet in-person with the U.S. Food and Drug Administration (FDA) before the e ...

SALT LAKE CITY, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at the H.C. Wainwright 26th Annual Global Investment Conference ...

Clene Inc. (CLNN) closed the last trading session at $5.65, gaining 24.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $55 indicates an 873.5% upside potential.The average comprises five short-term price targets ranging from a low of $20 to a high of $100, with a standard deviation of $38.64. While the lowest estimate indicates an increase of 254% from the current price level, t ...

Clene Inc. (CLNN) closed the last trading session at $5.11, gaining 2.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $55 indicates a 976.3% upside potential.The average comprises five short-term price targets ranging from a low of $20 to a high of $100, with a standard deviation of $38.64. While the lowest estimate indicates an increase of 291.4% from the current price level, t ...

Clene Inc. (CLNN) came out with a quarterly loss of $1.06 per share versus the Zacks Consensus Estimate of a loss of $1.60. This compares to loss of $2.40 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 33.75%. A quarter ago, it was expected that this company would post a loss of $1.80 per share when it actually produced a loss of $1.80, delivering no surprise.Over the last four quarters, the company has surpassed consensus EP ...